Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial.
Renata Walewska, Talha Munir, Manali Kamdar, Ian W Flinn, John M Pagel, Alan Skarbnik, Wojciech Jurczak, Miklos Egyed, Jeff P Sharman, Gillian Corbett, Florence Cymbalista, John C Byrd, Sofia Wong, Min Hui Wang, Priti Patel, Veerendra Munugalavadla, Raquel Izumi, William G Wierda, Gilles Salles, Jennifer A Woyach, Ann Janssens, Paolo Ghia, Karin Karlsson, Patricia Walker, George Follows, Steven Coutre, Versha Banerji, Yair Herishanu, Laura Maria Fogliatto
Lancet (London, England) 2020;395(10232):1278-1291